We here use knockin mutagenesis in the mouse to model the spectrum of acquired CEBPA mutations in human acute myeloid leukemia. We find that C-terminal C/EBPalpha mutations increase the proliferation of long-term hematopoietic stem cells (LT-HSCs) in a cell-intrinsic manner and override normal HSC homeostasis, leading to expansion of premalignant HSCs. However, such mutations impair myeloid programming of HSCs and block myeloid lineage commitment when homozygous. In contrast, N-terminal C/EBPalpha mutations are silent with regards to HSC expansion, but allow the formation of committed myeloid progenitors, the templates for leukemia-initiating cells. The combination of N- and C-terminal C/EBPalpha mutations incorporates both features, accele...
Biallelic CEBPA mutations and FMS-like tyrosine kinase receptor 3 (FLT3) length mutations are freque...
Leukemia-initiating cells can originate from hematopoietic progenitor cells that have acquired self-...
SummaryMutations in the CEBPA gene are present in 7%–10% of human patients with acute myeloid leukem...
SummaryWe here use knockin mutagenesis in the mouse to model the spectrum of acquired CEBPA mutation...
We here use knockin mutagenesis in the mouse to model the spectrum of acquired CEBPA mutations in hu...
SummaryWe here use knockin mutagenesis in the mouse to model the spectrum of acquired CEBPA mutation...
In a recent study published in Cancer Cell, Bereshchenko and colleagues (2009) report a knockin mous...
Leukemia-initiating cells can originate from hematopoietic progenitor cells that have acquired self-...
The CEBPA gene encodes a transcription factor protein that is crucial for granulocytic differentiati...
Mutations in the CEBPA gene are present in 7%-10% of human patients with acute myeloid leukemia (AML...
Biallelic CEBPA mutations and FLT3 length mutations are frequently identified in human acute myeloid...
SummaryMutations in the CEBPA gene are present in 7%–10% of human patients with acute myeloid leukem...
Mutations in the CEBPA gene are present in 7%-10% of human patients with acute myeloid leukemia (AML...
Biallelic CEBPA mutations and FMS-like tyrosine kinase receptor 3 (FLT3) length mutations are freque...
Acute myeloid leukaemia (AML) is an aggressive malignancy of the bone marrow caused by the uncontrol...
Biallelic CEBPA mutations and FMS-like tyrosine kinase receptor 3 (FLT3) length mutations are freque...
Leukemia-initiating cells can originate from hematopoietic progenitor cells that have acquired self-...
SummaryMutations in the CEBPA gene are present in 7%–10% of human patients with acute myeloid leukem...
SummaryWe here use knockin mutagenesis in the mouse to model the spectrum of acquired CEBPA mutation...
We here use knockin mutagenesis in the mouse to model the spectrum of acquired CEBPA mutations in hu...
SummaryWe here use knockin mutagenesis in the mouse to model the spectrum of acquired CEBPA mutation...
In a recent study published in Cancer Cell, Bereshchenko and colleagues (2009) report a knockin mous...
Leukemia-initiating cells can originate from hematopoietic progenitor cells that have acquired self-...
The CEBPA gene encodes a transcription factor protein that is crucial for granulocytic differentiati...
Mutations in the CEBPA gene are present in 7%-10% of human patients with acute myeloid leukemia (AML...
Biallelic CEBPA mutations and FLT3 length mutations are frequently identified in human acute myeloid...
SummaryMutations in the CEBPA gene are present in 7%–10% of human patients with acute myeloid leukem...
Mutations in the CEBPA gene are present in 7%-10% of human patients with acute myeloid leukemia (AML...
Biallelic CEBPA mutations and FMS-like tyrosine kinase receptor 3 (FLT3) length mutations are freque...
Acute myeloid leukaemia (AML) is an aggressive malignancy of the bone marrow caused by the uncontrol...
Biallelic CEBPA mutations and FMS-like tyrosine kinase receptor 3 (FLT3) length mutations are freque...
Leukemia-initiating cells can originate from hematopoietic progenitor cells that have acquired self-...
SummaryMutations in the CEBPA gene are present in 7%–10% of human patients with acute myeloid leukem...